Profile of Diabetes Mellitus Therapy in COVID-19 Patients with Diabetes Mellitus in Kogabwilhan II Emergency Hospital Surabaya

Ni Putu Ayu Deviana Gayatri, Didik Hasmono, Erwin Astha Triyono, Halim Priyahau Jaya, Sandra Junita Parambang

Research output: Chapter in Book/Report/Conference proceedingConference contributionpeer-review

Abstract

Diabetes mellitus is common comorbidity found in COVID-19 patients, increasing the severity of clinical symptoms and mortality rate. Several studies found that reasonable glycemic control significantly improved the clinical outcomes in diabetic COVID-19 patients. Regular blood glucose monitoring followed by optimal use of antidiabetic therapy is one of the solutions. The aims of this study are to analyze patient characteristics, clinical symptoms, the profile of diabetes mellitus therapy, and the length of hospital stay of COVID-19 patients with diabetes mellitus at KOGABWILHAN II Emergency Hospital Surabaya on May-December 2020. This study uses a cross-sectional analytic design. A total of 106 patients was enrolled in this study. Demographic data, clinical characteristics, length of hospital stay, and therapy profile are presented in tables and graphs. Data analysis was performed using SPSS version 25. The correlation analysis using the Chi-Square and Spearman test; the differences between variables were analyzed using the Mann-Whitney U test. Most of the patients in this study (61.32%) experienced mild symptoms such as productive cough (33.02%), nonproductive cough (16.04%), and headache (13.21%). The two most common antidiabetic were glimepiride (14.15%) and a combination of insulin detemir + insulin glulisine (2.83%). Based on analysis of 64 patients, the combination of glimepiride (1x2mg) + Metformin 500 mg (2x500 mg) PO had the shortest median rate of change in fasting blood glucose (2 days), with a median length of hospital stay eight days. Most of the patients in this study (44.34%) did not meet the therapy goal of post-therapy FBG <130 mg/dL. Almost half of the patients in this study were hospitalized for 6-10 days (49.06%). We conclude that the treatment of diabetes mellitus in this study did not achieve the expected therapeutic outcomes, and further research is needed to obtain better diabetes treatment management in COVID-19 patients.

Original languageEnglish
Title of host publicationAIP Conference Proceedings
EditorsMuhammad Nabil Mohd Warid, Muhammed Abdullah Al Sayem Khan
PublisherAmerican Institute of Physics Inc.
Edition1
ISBN (Electronic)9780735447295
DOIs
Publication statusPublished - 21 Nov 2023
Event1st Technology and Policy for Supporting Implementation of COVID-19 Response and Recovery Plan in Southeast Asia, ITTP-COVID19 2021 - Virtual, Online, Malaysia
Duration: 6 Aug 20218 Aug 2021

Publication series

NameAIP Conference Proceedings
Number1
Volume2739
ISSN (Print)0094-243X
ISSN (Electronic)1551-7616

Conference

Conference1st Technology and Policy for Supporting Implementation of COVID-19 Response and Recovery Plan in Southeast Asia, ITTP-COVID19 2021
Country/TerritoryMalaysia
CityVirtual, Online
Period6/08/218/08/21

Fingerprint

Dive into the research topics of 'Profile of Diabetes Mellitus Therapy in COVID-19 Patients with Diabetes Mellitus in Kogabwilhan II Emergency Hospital Surabaya'. Together they form a unique fingerprint.

Cite this